Two hundred twenty-eight members of the House of Representatives yesterday urged the Centers for Medicare & Medicaid Services to abandon its proposal to reduce Medicare Part B payment for drugs acquired through the 340B Drug Pricing Program. “Given the important role that the 340B program plays in our communities, we strongly urge CMS to abandon this proposal and redirect its efforts toward actions to address the cost of drugs via other policies that would not harm our constituents,” the representatives wrote. CMS has proposed to pay for separately payable, non pass-through drugs purchased through the 340B program at the average sales price minus 22.5%, rather than the current rate of ASP plus 6%. Reps. David McKinley (R-WV), Mike Thompson (D-CA) and David Kustoff (R-TN) spearheaded the letter. “The AHA thanks Representatives McKinley, Thompson, and Kustoff for leading this bipartisan effort to protect patient care by urging CMS to rescind its misguided proposal to reduce Medicare Part B payments for 340B hospitals,” said AHA Executive Vice President Tom Nickels.

Headline
The Centers for Medicare & Medicaid Services Feb. 25 released a request for information on potential regulatory changes in a possible future…
Headline
The Health Resources and Services Administration Feb. 25 said it will extend the deadline to April 20 to receive comments on its request for information on…
Headline
The U.S. District Court for the District of Hawaii Feb. 23 denied a preliminary injunction requested by AstraZeneca in a case challenging the state’s law…
Headline
The Centers for Medicare & Medicaid Services Feb. 23 announced the development of its Medicare App Library. As part of the agency’s Health Technology…
Headline
The Congressional Budget Office has projected that the Hospital Insurance Trust Fund will have sufficient funds to pay full benefits until 2040 — 12 years…
Headline
The AHA, joined by several other national groups representing 340B hospitals, Feb. 19 urged the Health Resources and Services Administration to extend the…